137 related articles for article (PubMed ID: 29139252)
1. [Intensive hospital monitoring of Shuxuening injection in 30 209 cases].
Jiang JJ; Xie YM; Zhang Y; Li MQ; Zhao YB; Wen ZH; Li XL; Yi DH; Zhang YK
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2883-2888. PubMed ID: 29139252
[TBL] [Abstract][Full Text] [Related]
2. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
3. [32 546 intensive hospital monitoring cases of Shuxuetong injection].
Jiang JJ; Xie YM; Zhang Y; Yang ZX; Yi DH
Zhongguo Zhong Yao Za Zhi; 2016 Oct; 41(20):3852-3858. PubMed ID: 28929666
[TBL] [Abstract][Full Text] [Related]
4. [Clinical medication characteristics of Shuxuening injection in treatment of cerebral infarction research based on registration].
Jiang JJ; Xie YM; Zhang Y; Zhang YK; Wang ZM; Han B
Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4516-4520. PubMed ID: 28936832
[TBL] [Abstract][Full Text] [Related]
5. [Apply association rules to analysis adverse drug reactions of shuxuening injection based on spontaneous reporting system data].
Yang W; Xie YM; Xiang YY
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3616-20. PubMed ID: 25532406
[TBL] [Abstract][Full Text] [Related]
6. [Clinical safety imtensive hospital monitoring on Shenfu injection with 30 106 cases].
Wang ZF; Yu JY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2871-2876. PubMed ID: 29139250
[TBL] [Abstract][Full Text] [Related]
7. [Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].
Wang LX; Xie YM; Ai QH; Xu WF
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4739-45. PubMed ID: 27245015
[TBL] [Abstract][Full Text] [Related]
8. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Yang W; Xiang YY; Xie YM; Shen H
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
[TBL] [Abstract][Full Text] [Related]
10. Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Zhu JH
Drug Des Devel Ther; 2018; 12():757-767. PubMed ID: 29670332
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of clinical effects of shuxuening injectionon renal function based on hospital information system data].
Chen J; Xie YM; Yang W; Wang YY; You L; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3599-605. PubMed ID: 25532403
[TBL] [Abstract][Full Text] [Related]
12. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
13. [Analysis effects of shuxuening injection on patient's liver function based on electronic medical data].
Hao TT; Xie YM; Yang W; Wang YY; Li L; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3609-15. PubMed ID: 25532405
[TBL] [Abstract][Full Text] [Related]
14. [Post-marketing intensive safety monitoring of Injection of Xuesaitong (lyophilized) in 30097 cases].
Xin-Yao J; Ke-Yi W; Jing-Bo Z; Chun-Xiang L; Hui W; Zhi L; Wen-Tai P; Hu-Cheng W; Nan LI; Jun-Hua Z; Wen-Ke Z
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):5029-5033. PubMed ID: 33350279
[TBL] [Abstract][Full Text] [Related]
15. [Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].
Wang LX; Xie YM; Ai QH; Song NB
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4752-6. PubMed ID: 27245017
[TBL] [Abstract][Full Text] [Related]
16. [Adverse reactions occurred in four cases induced by intravenous injection of Alprostadil and Shuxuening Injection in normal saline].
Shi L; Guo GM
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Dec; 35(12):1524-5. PubMed ID: 26882620
[No Abstract] [Full Text] [Related]
17. [Retrospective analysis and discussion on 74 cases of adverse reactions of traditional Chinese medicine injection].
Wang Y; Fan LP; Song J; Cai YP; Jinang TT; Wang YG; Kong XW; Wu JR
Zhongguo Zhong Yao Za Zhi; 2018 Nov; 43(21):4347-4351. PubMed ID: 30583639
[TBL] [Abstract][Full Text] [Related]
18. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
20. [Overview of systematic reviews on Shuxuening Injection].
Gao Y; Liu M; Shi SZ; Yang KL; Tian JH
Zhongguo Zhong Yao Za Zhi; 2021 Jul; 46(14):3712-3721. PubMed ID: 34402296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
